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Vagusolism is controlled by the brain, in which key central neuronal circuits process a
variety of information reﬂecting nutritional state. Special sensory and gastrointestinal afferent neural signals,
along with blood-borne metabolic signals, impinge on parallel central autonomic circuits located in the
brainstem and hypothalamus to signal changes in metabolic balance. Speciﬁcally, neural and humoral signals
converge on the brainstem vagal system and similar signals concentrate in the hypothalamus, with
signiﬁcant overlap between both sensory and motor components of each system and extensive cross-talk
between the systems. This ultimately results in production of coordinated regulatory autonomic and
neuroendocrine cues to maintain energy homeostasis. Therapeutic metabolic adjustments can be
accomplished by modulating viscerosensory input or autonomic motor output, including altering
parasympathetic circuitry related to GI, pancreas, and liver regulation. These alterations can include
pharmacological manipulation, but surgical modiﬁcation of neural signaling should also be considered. In
addition, central control of visceral function is often compromised by diabetes mellitus, indicating that circuit
modiﬁcation should be studied in the context of its effect on neurons in the diabetic state. Diabetes has
traditionally been handled as a peripheral metabolic disease, but the central nervous system plays a crucial
role in regulating glucose homeostasis. This review focuses on key autonomic brain areas associated with
management of energy homeostasis and functional changes in these areas associated with the development
of diabetes.
© 2008 Elsevier B.V. All rights reserved.Energy homeostasis is largely controlled by the brain, where
information reﬂecting nutritional state is processed, eventually
leading to regulatory signals along the autonomic and neuroendocrine
axes. Afferent indicators of energy balance include sensory signals
(e.g., taste), gastrointestinal (GI) neural signals arising frommechano-
and chemoreceptors in the stomach, andmetabolic signals detected in
blood (e.g., insulin, glucose, leptin). These signals are integrated and
processed in central autonomic control centers, located principally in
the brainstem and hypothalamus [1]. Treatments proposed for
adjusting metabolism are often aimed at modulating neural circuits
making up the efferent limb of energy homeostasis, including
parasympathetic circuitry related to GI, pancreas, and liver regulation.
Likewise, vagal control of the viscera can be compromised by
pathology, including diabetes mellitus [2]. Impairment of neuronal
signaling can adversely affect autonomic output, resulting in increased
feeding, weight gain, and altered hepatic glucose metabolism. Under-
standing the mechanisms governing parasympathetic output to the
viscera may beneﬁt the development of direct therapies for disorders
of energy homeostasis. A model of the interactions between
hypothalamic and brainstem autonomic nuclei with the periphery is+1 859 323 1070.
ll rights reserved.illustrated in Fig. 1. In order to study these mechanisms, local control
of neurons regulating autonomic functions must be understood.
Diabetes mellitus is the most common metabolic disorder in
humans and a rather pessimistic prognosis suggests that the disease
most likely will be one of the major public health problems in the next
decades [3]. Diabetes mellitus is characterized by chronic hypergly-
cemia due to insulin deﬁciency in the case of type 1 diabetes or insulin
resistance in the case of type 2 diabetes. The loss of pancreatic beta
cells in type 1 diabetes can be caused, for example, by viral infection or
autoimmune disease. Obesity, often considered as a disorder of energy
homeostasis, is strongly associated with risk for many diseases and
health conditions such as hypertension, coronary heart disease,
stroke, dyslipidemia, and notably, type 2 diabetes.
Diabetes has traditionally been handled as a peripheral metabolic
disease. But recently, non-invasive brain imaging techniques provid-
ing information on brain anatomy and function have indicated
structural and functional abnormalities associated with diabetes.
Computed tomography (CT) and magnetic resonance imaging (MRI)
studies describe a relationship between diabetes and cerebral atrophy
and lacunar infarcts [4]. Positron emission tomography (PET) and
single photon emission CT (SPECT) studies showed regional altera-
tions in cerebral blood ﬂow [4]. Cerebral edema, cerebral hemorrage,
or intracranial thrombosis was observed in children with type 1
diabetes and diabetic ketoacidosis [5]. Patients with type 2 diabetes
Fig. 1. Schematic of hypothesized parallel brain-digestive system-brain circuits in
hypothalamus and brainstem. Hypothalamic nuclei involved in autonomic regulation
and feeding make reciprocal connections with neurons in the dorsal vagal complex that
regulate visceral function. Within the vagal complex, the NTS receives visceral afferent
neural input and projects heavily to vagal motor neurons of the DMV. The NTS is also
reciprocally connected to hypothalamic nuclei involved in autonomic regulation,
especially the PVN. Both PVN and NTS also project to central sympathetic nervous
system regulatory centers. Likewise, both brainstem and hypothalamic areas receive
information about peptide and glucose content in the blood. Abbreviations: DMV,
dorsal motor nucleus of the vagus; IML, intermediolateral cell column; LH, lateral
hypothalamus; NTS, nucleus tractus solitarius; PVN, paraventricular nucleus; VLM,
ventrolateral medulla; VMH, ventromedial hypothalamus.
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brain imaging techniques [6]. All these observations suggest that
diabetes has a strong effect on brain function and inﬂuencing this
systemmight positively improve the life expectancy and quality of life
for diabetic patients.Fig. 2. A simpliﬁed diagram illustrating a basic-circuit connection between preautonomic ne
how energy-regulating factors can inﬂuence central autonomic circuits. Somatodendritic KAT
leptin and insulin receptors and glucose sensors, all of which can utilize kinases to affect cellu
GABA critically regulates motor neuron function and its release is in the DMV is illustrated. G
neurotransmitter release is omitted for simplicity, but may also occur.Areas of the brain that regulate autonomic and neuroendocrine
functions have been the subject of increasingly intense analysis in the
context of understanding diabetes and other metabolic disorders [7–
10]. The central nervous system plays a crucial role in regulating
glucose homeostasis, including hepatic gluconeogenesis and glyco-
genolysis and pancreatic function. These activities are largely
mediated by central regulation of the autonomic nervous system,
which acts in concert with the hypothalamic-pituitary-adrenal axis to
regulate metabolic responses to changes in energy requirements and
plasma glucose concentration. In particular, critical autonomic
regulatory neurons in the hypothalamus and brainstem are respon-
sible for management of energy homeostasis (Fig. 1), and functional
changes in these areas are associated with the development of
diabetes [7].
The brainstem dorsal vagal complex (DVC), which includes as
primary components the nucleus tractus solitarius (NTS) and dorsal
motor nucleus of the vagus nerve (DMV), plays a critical role in the
autonomic parasympathetic control of energy homeostasis, through
activation of the vagus nerve. Neurons controlling the vagus nerve
functionally regulate gastrointestinal motility as well as liver,
pancreas, and other organs, and these functions appear to be
signiﬁcantly altered in diabetes (Fig. 2). The NTS is the ﬁrst site of
central synaptic contact for sensory afferent ﬁbers of cranial nerves
VII, IX, and X, including viscerosensory vagal afferents. Themotor limb
of the subdiaphragmatic vagus nerve originates mainly in neurons of
the DMV. Neuronal connections within the DVC form the basis for
reﬂex control of visceral parasympathetic function. Thus, for example,
activation of mechanoreceptors in the stomach wall by passive
distention, active contraction, or chemoactivation of the stomach
increases the ﬁring rate in primary vagal afferent ﬁbers, and results in
rapid cessation of feeding when the stomach becomes full [11–16].
Descending input to the DVC, especially from the hypothalamic
paraventricular nucleus (PVN), modulates the satiety-producing
effects of gastric vagal afferent activation. Activation of the efferent
vagus normally acts to upregulate many digestive and other
parasympathetic functions, but with appropriate stimulation it can
also play a role in negatively modulating metabolic functions,
including hepatic gluconeogenesis [17]. Such negative control of
vagal output is illustrated in Fig. 2, where GABA is released onto DMV
motor neurons from terminals of preautonomic neurons located
mainly in the NTS.
Along with the NTS, the PVN is a key central structure involved
in integrating afferent autonomic information and coordinatingurons and parasympathetic, preganglionic motor neurons in the context of a model for
P channels, with Kir6.2 and SUR subunits are shown in both types of cell. Also shown are
lar activity. Glucokinase and PI3K are indicated, but AMPK can alsomediate some effects.
eneral pertinent vagally-mediated visceral effects are listed. Altered glutamate or other
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neurons in PVN receive parasympathetic-related neural information
from the NTS, as well as from feeding-related neurons in the
ventromedial (VMH) and lateral (LH) hypothalamic nuclei, central
hypothalamic areas that can detect circulating indicators of meta-
bolic state such as glucose, leptin, ghrelin, and insulin. Neurons in
the vagal complex are also capable of detecting peptide and glucose
levels in the blood, so PVN responses to circulating signals can also
arise from extrahypothalamic neural sources (Fig. 1). Preautonomic
neurons in the PVN are connected to sympathetic and parasympa-
thetic visceral motor circuits through descending projections to the
NTS, DMV, ventrolateral medulla, and spinal cord; premotor NTS
neurons also participate in autonomic motor regulation via projec-
tions to PVN, DMV, and ventrolateral medulla. The PVN and NTS
thus receive direct and indirect neural and blood-borne information
about metabolic state and digestive system activity, process that
information, and directly contribute to coordinated autonomic
output to the viscera. These areas thus represent parallel systems
for integrating visceral sensory-motor information that is crucial for
maintaining metabolic balance.
1. Brain-responses to metabolic indicators
Although it is well known that select neurons in the CNS
respond to changes in plasma glucose concentration – especially
hypoglycemia – the role of the brain in the normal regulation of
glucose homeostasis is not adequately understood. Neurons in
central autonomic areas participate in regulating peripheral glucose
metabolism. Chemical or electrical stimulation of LH increases
parasympathetic nervous system activation and was shown to
reduce blood glucose levels by increasing glycogen synthesis in the
liver [18,19]. To the contrary, stimulation of VMH results in
sympathetic nervous system activation and a subsequent rise in
blood glucose concentration that was mediated by hepatic
glycogenolysis [19]. More selective neurochemical activation of
these and other hypothalamic areas often results in less well-
segregated responses [20–22], possibly due to the non-selective
activation of ﬁber pathways by electrical stimulation or the more
discreet activation of subsets of neurons in these regions by
chemical activation. Denervation studies further support the idea
that CNS plays a key role in hepatic glucose regulation [17,23,24].
Activation of parasympathetic motor output is not normally
associated with large changes glucose production by the liver, but
systemic insulin-induced suppression of hepatic gluconeogenesis
was diminished by approximately half after hepatic branch
vagotomy, indicating that the vagus nerve mediates a large portion
of the insulin-mediated neural regulation of glucose production
[17]. Effects of metabolic signals on peripheral nervous systems and
visceral smooth muscle thus work in concert with effects on
central components to modulate visceral functions. In addition to
widely-studied peripheral effects on glucose metabolism, insulin
can act at receptors in the hypothalamus and possibly also in the
DVC to affect parasympathetic motor control.
2. Leptin and insulin action on KATP channels
In addition to regulation of glucose metabolism, these same
brain areas participate in responses to circulating peptides that are
critical regulators of energy homeostasis, including insulin and
leptin [25]. Leptin receptors have been localized in many
hypothalamic and brainstem autonomic nuclei [26]. Application of
leptin to neurons of hypothalamic arcuate and ventromedial nuclei
decreased the ﬁring rate of action potentials and input resistance
[27] in control Sprague–Dawley and lean – but not obese – Zucker
rats, which have a mutation of leptin receptor gene, causing
hypothalamic insensitivity to leptin. The leptin-sensitive neuronswere also sensitive to changes in glucose concentration, and the
effects of leptin in these glucose-responsive neurons were
prevented by the sulphonylurea, tolbutamide [27]. These observa-
tions suggested that the leptin-induced hyperpolarization was due
to a current resultant from opening of ATP-sensitive K+ channels
(KATP; Fig. 2). The lack of leptin response in glucose-responsive
neurons from obese Zucker rats indicates that functional leptin
receptors are required for hyperpolarizing this brain area and
explains the reduced effectiveness of leptin in reducing food intake
and body weight gain when injected into the hypothalamus of
obese rats [28,29]. Tolbutamide-sensitive leptin effects were also
observed in the dorsal vagal complex. Application of leptin caused
a rapid membrane hyperpolarization in half of the NTS neurons
sampled and the hyperpolarizing effect of leptin was prevented
with tolbutamide or wortmannin, indicating activation of KATP
channel via a PI3 kinase-dependent mechanism [30]. The leptin-
induced hyperpolarization was also observed in gastric-related
DMV neurons, and tolbutamide reversed this effect. Further, leptin
reduced the frequency of spontaneous and miniature EPSCs,
whereas the IPSCs were unaffected in both NTS and DMV neurons
[31]. This suggests that leptin is able to suppress activity of
excitatory NTS and DMV neurons that are likely to be involved in
regulation of GI tract.
Insulin and leptin can both reduce food intake and body weight.
Insulin inhibited hypothalamic glucose-responsive neurons, causing a
decreased ﬁring rate, hyperpolarization and increased conductance in
control and lean animals, but not in obese rats [32], similar to effects of
leptin. Tolbutamide reversed the effect of insulin or glucose on
membrane potential, supporting the hypothesis that insulin acted via
KATP channels on glucose-responsive neurons of control and lean, but
not obese rats. The time course of effects on feeding (hours) and
effects on membrane channels (seconds) are dramatically different,
implying the link between peptide or glucose infusion and neuronal
activity may be far removed or even disconnected from effects on
feeding. The effects are nonetheless consistent with previous
observations that intracerebroventricular injection of insulin reduces
food intake and body weight of lean, but not obese, leptin deﬁcient
rats [33]. Notably, effects of leptin on body weight and feeding are also
known to occur subsequent to infusion of the peptide into the DVC
[34]. These data together with other observations [27,29] are
consistent with the hypothesis that the ability of insulin to activate
KATP channels in glucose-responsive neurons and to decrease food
intake and body weight in these animals depends on the normal
functioning of a brain-leptin pathway. The suggested convergence of
leptin and insulin on KATP channels is illustrated in Fig. 2.
Mice deﬁcient in leptin itself (ob−/ob−) or leptin receptor (db−/
db−) become diabetic and obese. Activation of these receptors on
neurons, or the subsequent downstream effects of altered neuronal
circuitry are apparently involved in regulating metabolic homeostasis.
In addition to direct effects of glucose-, insulin-, or leptin-mediated
KATP channel modulation on membrane potential and action potential
frequency, these factors also inﬂuence the release of the classical fast
neurotransmitters in the brain, glutamate and GABA.
3. Glucose-responsive neurons and KATP channels
Glucose-responsive neurons use glucose to regulate their ﬁring
rate by altering the activity of the KATP channel [35]. In the last
25 years KATP channels have been found in many different tissues,
including pancreatic β cells and neurons. KATP channels are able to
couple cell metabolism to the electrical activity of the neurons and
transfer the effects of hormones and neurotransmitters on membrane
potential [36]. The KATP channel has two types of subunit, an inwardly
rectifying K+-channel subunit (Kir6.2) and a sulphonylurea receptor
subunit (SUR) [37]. Both subunits are necessary to form a functional
KATP channel (Fig. 2).
Fig. 3. Schematic model illustrating cannabinoid and vanilloid activity in central auto-
nomic circuits. A synaptic terminal (glutamatergic or GABAergic) is shown, containing
TRPV1 and CB1R. Anandamide (AEA) is illustrated as an example of an endogenously
synthesized cannabinoid (eCB) agonist that can bind both receptors. Synthesis and
retrograde release of eCB from postganglionic neurons is suggested. TRPV1 are non-
selective cation channels that are also activated by capsaicin and ﬂux Ca2+, resulting in
increased synaptic release. CB1R are G protein-coupled receptors that can also be
activated by the synthetic agonist,WIN 55,212-02. Binding CB1R on typically suppresses
neurotransmitter release.
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increase in the ATP/ADP ratio, which promotes ATP binding to the
channel complex. This inactivates (closes) the channel, leading to
intracellular K+-accumulation followed by membrane depolariza-
tion, calcium inﬂux and increased cell ﬁring. When glucose supply
is limited, the ATP/ADP ratio falls, the KATP channel opens
(activates), and the cell membrane becomes hyperpolarized and
neuronal ﬁring decreases [35,38]. Deletion of Kir6.2 subunits of KATP
channel cause failure in glucose mobilization and feeding responses
[35], and glucose-responsive neurons in DVC expressed Kir6.2
subunits as well as glucokinase, which was not expressed by glia or
in neurons that were not responsive to glucose [39]. These obser-
vations suggest that an intact KATP channel is critical to the func-
tioning of glucose-responsive neurons in the hypothalamus and
brainstem.
The KATP channel activator, diazoxide injected into the third
cerebral ventricle signiﬁcantly decreased hepatic glucose production
through central stimulation of KATP. The decrease in glucose produc-
tion was due to inhibition of gluconeogenesis, while the rate of
glycogenolysis was not decreased [17]. Application of insulin repro-
duced the effect of diazoxide. These observations suggested that direct
activation of central KATP channels mimic the action of insulin on
hepatic gluconeogenesis. Thus, activation of either KATP channels or
insulin signaling within the medial hypothalamus is adequate to
decrease blood glucose levels through suppression of glucose
production by the liver [17]. Blocking KATP channels with sulphony-
lureas (e.g., tolbutamide or glibenclamide) prevented the activation of
KATP channels by glucose, insulin, and leptin [31,32,40]. These
experiments suggested that modulation of hypothalamic and/or
brainstem KATP channel activity likely plays an important role in
regulation of glucose homeostasis. The central autonomic KATP
channel may be a therapeutic target for regulating glucose levels in
diabetes mellitus.
In addition to KATP-channels, glucose can alter neuronal function
via AMP kinase (AMPK), an enzyme that is regulated by the relative
concentrations of AMP and ATP. This is especially true for neurons that
are inhibited by glucose, as occurs in the ventromedial hypothalamus[41,42]. Thus, neurons in the hypothalamus and brainstem can react to
changing glucose levels via different mechanisms.
4. The DVC and glucose sensitivity
In the DVC, activity of neurons could be either increased by glucose
or increased by removal of glucose, suggesting responses to both
hypo- and hyperglycemia [39,43]. Most effects were associated with
the presence of SUR1, a nearly ubiquitously-expressed KATP channel
subunit that also imparts effective KATP channels in hypothalamus,
although a hypoglycemia-induced depolarization was attributed to a
different mechanism. Effects were associated with expression of
Kir6.2 channel protein and more selectively with glucokinase
expression [39]. The effects of altered glucose concentration in
unidentiﬁed vagal complex neurons were thus attributed to effects
on KATP-mediated currents in neurons that also expressed glucoki-
nase. Although glucose transporters are expressed in several brain
areas, their presence in vascular epithelium may not be necessary in
the vagal complex due to the presence of fenestrated capillaries in the
NTS, which would allow direct access of the neurons to glucose and
other large molecules [44].
The NTS is primarily viscerosensory in nature, receiving direct,
obligatory viscerosensory innervation from the organs of the thorax
and abdomen. Direct glucose sensing might allow for moment-to-
momentmonitoring of plasma glucose concentration by the brain. The
NTS connects directly with neurons in the hypothalamic PVN that
control feeding and digestion as well as with gastrointestinal-,
hepatic-, and pancreatic-projecting motor neurons in the DMV and
with pre-sympathetic neurons in the ventral brainstem (Fig. 1).
Although DMV neurons themselves might sense glucose levels
directly, since their dendrites extend well into the NTS [45], elevated
glucose in slices resulted a TTX and picrotoxin sensitive outward
current in these cells [40]. Although inconsistent with other studies
showing a lack of Cl−-dependence to the effect of altered glucose
concentration [39], the inhibitory effect of glucose application in DMV
motor neurons was prevented by blocking action potentials and was
consistent with an increase in Cl− conductance [40]. The effect was
therefore hypothesized to be indirect, being due to activation of a local
GABAergic circuit. A major inhibitory GABAergic input to gastric-
related and other DMV motor neurons arises from the adjacent NTS
[46,47], so these results were consistent with glucose elevation
activating GABAergic NTS neurons, which in turn suppressed activity
of preganglionic vagal motor neurons (Fig. 2).
This precise arrangement has not been tested directly, but injecting
glucose in the DVC also caused a decrease in gastric motility and an
increase in intragastric pressure [40]). Consistent with these effects,
vagal nerve activity is suppressed in acute hyperglycemia [48], leading
to decreased parasympathetic visceral tone. Vagally-mediated gastric
regulation is severely compromised in hyperglycemic animals and
human patients. Both gastric hyperactivity and gastroparesis are
reported, and these are due, at least in part, to vagal dysregulation
[49]; gastrointestinal dysfunction in diabetics is often seen in
otherwise asymptomatic patients. Vagal involvement in diabetes is
also suggested by the ﬁnding that hepatic vagal lesions potently
suppress insulin-induced normalization of hepatic gluconeogenesis
[17]. Glycemic control of DMV neurons projecting to the pancreas or
liver, which are known to regulate insulin and glucose production,
respectively, has never been assessed. However, understanding how
glucose and GABAergic interact to regulate DMV neurons could aid in
normalizing digestive functions and metabolic homeostasis in
diabetic patients.
5. Role of the hypothalamus in diabetes mellitus
The hypothalamus is known as a crucial center for controlling
feeding behavior, energy balance and glucose homeostasis. Neurons
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hyperglycemia via different cellular pathways (i.e., KATP-mediated
excitation and AMPK-mediated inhibition), resulting in glucagon
release from the pancreas and secretion of epinephrine [50,51]. It
has long been known that electrical stimulation of the areas of the
hypothalamus corresponding to glucose-sensing regions (i.e., VMH,
LH) activates glycogen synthase [52], and stimulation of VMH
triggers glycogenolysis in the liver [18]. Focal lesions in the area of
VMH abolish the hormonal response to systemic hypoglycemia,
suggesting the importance and the role of the VMH in the counter-
regulatory mechanism [50,51,53]. Magnusson et al. [54] made the
remarkable observation that increased hepatic gluconeogenesis
contributes signiﬁcantly to hyperglycemia in type 2 diabetes. The
role of the hypothalamus was further highlighted after Obici et al.
demonstrated that modulation of lipid metabolism within the
hypothalamus causes changes in energy balance and glucose
metabolism [55–58].
6. POMC neurons
Over the last three decades it has become evident that both insulin
and leptin activate receptors in several brain areas including the
hypothalamus [59–61]. There is increasing evidence suggesting that
insulin and leptin penetrate the blood brain barrier (probably
indirectly via a transporter) and activate their receptors in several
brain areas including the hypothalamus [59–61]. However, just a small
portion of peripherally-applied insulin reaches the CNS, and the
transport of insulin has a saturable character [50,62]. Transport is
altered during different physiological conditions such as fasting,
obesity or diabetes [63]. But the origin of central insulin remains
unclear, as other studies assert that insulin is made in the brain [10].
Increased levels of insulin and leptin activate a group of hypothalamic
neurons that synthesize the peptide proopiomelanocortin (POMC).
Activation of POMC neurons can inﬂuence body weight feeding, and
energybalance [64,65]. Consistentwith responses to leptin and insulin,
POMCneurons also respond to glucose and express KATP channels [66].
In addition tothehypothalamus, a signiﬁcantnumberofPOMCneurons
are located in the NTS, although little is known about their physiology
[67]. Parton et al. [68] observed that nearly half of the population of
hypothalamic POMC neurons was glucose-excited; this may in turn
regulate glucose homeostasis via connections with the PVN and/or
brainstem. Disruption of glucose sensing in glucose-excited POMC
neurons via genetic manipulation of the KATP channels –wherein KATP
channels are 250 times less sensitive to closure by ATP – resulted in
impaired responses to glucose tolerance tests [68],which suggests that
glucose-sensing by glucose-excited POMC neurons is required for the
normal handling of systemic glucose load. The study also provided
evidence that the glucose-sensing properties of POMC neurons is
diminished with obesity and that the mitochondrial protein uncou-
pling protein 2 (i.e., UCP2) is involved in this loss of glucose sensitivity.
Thus, speciﬁc responses in this subset of neurons may represent an
important pathogenic component of type 2 diabetes [68]. Responses in
other cell groups have yet to be determined.
7. Other metabolic signals
Roles of histamine, dopamine, and serotonin on hypothalamic
control of feeding behavior have been identiﬁed in relation to
diabetes [53]. In addition, a large number of neuropeptides and
circulating hormones have been identiﬁed, which can modify
ingestion and other homeostatic functions and thus can affect
outcomes in diabetes. Over the last 10 years, ghrelin, a 28-amino-
acid protein hormone released mainly from the stomach, has
garnered a great deal of attention with respect to diabetes because
it is thought to stimulate appetite. The hypothalamus and the DVC
are the thought to be among the areas affected by ghrelin. Plasmaghrelin levels rise in fasted animals and increased ghrelin tends to
increase feeding. These relationships were lost after vagotomy [69],
indicating that ghrelin's effects in the brain are at least partly
mediated by vagal connections with the viscera. It is widely
appreciated that that ghrelin increases appetite in part by
depolarizing hypothalamic orexigenic neuropeptide Y (NPY)/
agouti-related protein (AgRP) neurons or by increasing the tonic
inhibition exerted by the NPY/AgRP neurons over the POMC
neurons [69]. Ghrelin stimulates AMPK in the hypothalamus and
increases food intake [25]. Food, glucose deprivation, and adminis-
tration of an AgRP antagonist can also increase AMPK activity in the
hypothalamus. Ghrelin and endogenous cannabinoids increase
hypothalamic AMPK activity and leptin or insulin decreases it [25].
Fasting ghrelin concentrations are lower in type 2 diabetic patients
compared to non-diabetic controls, and the diminished circulating
ghrelin concentration is proportionate to the degree of insulin
insensitivity. In type 1 diabetes ghrelin levels are elevated, and the
elevation is reduced by insulin treatment. Reduction of ghrelin levels
depends on the presence of circulating insulin. In STZ-induced
uncontrolled diabetes, hyperphagia is thought to be due to deﬁcient
hypothalamic signaling by insulin and leptin, which in turns lead to the
activation of NPY/AgRP neurons.Whereas food intake did not increase
until three days after STZ administration, plasma ghrelin levels were
increased within one day [70]. As hyperphagia developed, plasma
ghrelin levels declined. The authors concluded that uncontrolled type 1
diabetes increases both circulating ghrelin levels and sensitivity to
ghrelin. These observations support the idea that increased ghrelin
signaling contributes to the pathogenesis of diabetic hyperphagia. The
exact action of ghrelin to controlling feeding behavior is not clear yet,
but evidence suggests that ghrelin has a role in the control of energy
balance and body weight in diabetic patients.
8. Plasticity of neuronal function in diabetes
Emerging evidence suggests that hormonal and nutrient signals
acting within the CNS, particularly on nuclei of hypothalamus and
brainstem,playa critical role in regulatingglucosemetabolism. Plasticity
in hypothalamic and brainstem circuits regulating metabolism are thus
likely to participate in glucose metabolism in diabetes, either by
contributing to glucose metabolism dysregulation or by compensating
for changes associated with eating and metabolic disorders.
Speciﬁc neural pathways involved in autonomic regulation con-
tribute signiﬁcantly to both normal glucose metabolism and also to
altered responses to glucose in models of diabetes. Hyperactivity of
dorsal horn neurons in the spinal cord has been associated with
diabetic neuropathy in hyperglycemic rats [71], but synaptic changes
in these neurons are poorly understood. The frequency of glutama-
tergic miniature excitatory postsynaptic currents (mEPSCs) was
signiﬁcantly higher in animal models of type 1 diabetes than in
controls [72]. Preliminary observations likewise indicated increased
spontaneous EPSC frequency in DMV neurons recorded in acute
brainstem slices from diabetic mice [73]. The frequency of GABAergic
and glycinergic spontaneous inhibitory postsynaptic currents (sIPSCs)
and mIPSCs did not differ in control and diabetic animals in these
studies. Application of the GABAB agonist, baclofen produced a greater
decrease in frequency of mEPSCs in controls than in diabetic animals
[72], but the inhibitory effect on IPSCs was not different. These
ﬁndings suggest that increased glutamatergic input may contribute to
central manifestations of diabetes, including synaptic plasticity and
central sensitization in diabetic neuropathic pain.
In addition to indirect effects of glucose on synaptic transmission
[40], others have shown that glucose can acutely alter vagal responses
and neuronal membrane potential. In addition to acute effects on
synaptic transmission observed in the hypothalamus, spinal cord, and
brainstem, altered glucose levels lasting for longer periods of time
might alter neuronal communication in a manner consistent with
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elevations tend to inhibit vagal output, prolonged hyperglycemia can
induce vagally-stimulated insulin release [74] and can increase vagus
nerve activity tonically [75]. In patients with type 2 diabetes
gastrointestinal problems such as constipation, nausea, and abdominal
pain are very common [76]. It is not immediately apparent how this
effect over time is consistentwith the inhibition of DMV cells produced
by acute glucose application [40]. But the putative glucose-induced
increase inGABAneuron activity, which in turn enhancesGABA release
and thus GABAA receptor-mediated Cl− currents in the DMVmay, over
several days, be associated with long-term, possibly compensatory,
plastic changes in synaptic currents over time in the DMV.
The major fast inhibitory neurotransmitter in the brain is GABA. In
the NTS and DMV, all fast inhibitory postsynaptic currents (IPSCs), or
potentials (IPSPs) are completely blocked by GABAA receptor
antagonists, consistent with the prominence of GABA in the regulation
of the DVC (Travagli et al., 1991; Smith et al., 1998; Davis et al., 2004).
Molecular cloning studies have shown that the GABAA receptor gene
family encodes at least 21 different subunits, including α1–6, β1–4,
γ1–4, δ, ɛ, π, θ, and ρ1–3, which are thought to combine as
heteropentamers to form pharmacologically distinct receptor iso-
forms, withα1β2γ2 making upmost native synaptic GABAA receptors
[77]. In addition to synaptic inhibition, a GABAA receptor-mediated
“tonic GABAergic inhibition” (i.e., I-tonic), which is distinct from
synaptic inhibition in that I-tonic may result from activation of
extrasynaptic GABAA receptors after “spillover” of excess GABA
released from terminals [78], has been described in several brain
regions. The GABAA receptors mediating I-tonic are high afﬁnity
sensors activated by low concentrations of ambient GABA in the
extracellular space [79,80]. Based on their extrasynaptic location and
biophysical and pharmacological properties, the subunit composition
of the GABAA receptors mediating I-tonic often includes the δ subunit
in place of the γ2 subunit, in addition to 2α and 2β subunits [81–83].
In particular, GABAA receptors are highly plastic functionally, being
altered by changes in their environment. For example, after seizures in
mice, δ subunits are decreased in the dentate gyrus, contributing to
increased excitability. However, other subunits (γ2,α4) are increased,
and δ subunit expression is itself increased in a subset of interneurons
[84]. Excessive GABA induced a reduction in α subunit mRNA in
cultured embryonic neurons [85] and others have reported region-
and subunit-speciﬁc changes in GABAA receptors after elevation of
brain GABA in vivo [86,87]. These subunit modiﬁcations signiﬁcantly
affect the postsynaptic pharmacology and efﬁcacy of released GABA,
particularly at GABAA receptors mediating I-tonic. Thus, chronic
glucose-induced enhancement of GABA release in the DMV might
similarly alter postsynaptic responses to GABA in a compensatory
manner, which could account for some of the vagal hyperresponsive-
ness seen in diabetic patients. Vagal activity is a crucial component of
glucose metabolism and changes in vagal control might participate in
long-term dysregulation of glucose metabolism by altering neuronal
communication in the brainstem and hypothalamus.
Functional MRI studies have also shown that the hypothalamus is
more sensitive to glucose concentration changes in patients with type
1 diabetes than in non-diabetic controls [88]. Ingestion of a glucose
solution by type 2 diabetic patients and healthy controls resulted in a
prolonged and signiﬁcant blood oxygen level-dependent decrease in
activity in the hypothalamus of healthy subjects, but not in diabetic
patients [89]. Thus glucose failed to inhibit hypothalamus neuronal
activity in type 2 diabetes. These observations further support the
hypothesis that neuronal circuitry is modiﬁed in central autonomic
regions in patients with type 1or -2 diabetes.
9. Diabetes and modulated autonomic output
Early studies suggested that i.v. injection of glucose increased
efferent activity in the hepatic branch of the vagus nerve in the rat andi.v. administration of insulin suppressed this activity [18]. The effect of
central administration of insulin was also tested in rats with hepatic
branch vagotomy [17]. Systemic insulin decreased hepatic glucose
production in sham-operated animals, but the effect of insulin was
signiﬁcantly diminished by approximately half in animals that
underwent hepatic vagotomy. Likewise, the glucose-reducing actions
of insulin injected directly into the VMHwere eliminated by vagotomy
[24]. Efferent vagal control of the liver is therefore required for the
inhibition of glucose production following peripheral administration
of insulin, although visceral afferent input to the brainstem via the
hepatic branch of the vagus nerve may not be necessary. These
experiments support the hypothesis that increased circulating insulin
levels activate a neuronal hypothalamic-brainstem circuit that is
required in order to restrain hepatic gluconeogenesis [17,23].
10. Synaptic modulation and diabetes
Vagal afferent activation is a critical satiety signal and initiates the
feeling of “fullness” during a meal [90]. Central synaptic circuits
controlling the vagus nerve play a role in glucose homeostasis via
control of hepatic and pancreatic functions in addition to signaling
hypothalamic and other central regulators of metabolic homeostasis.
Synaptic balance is altered in the DVC of hyperglycemic/hypoinsu-
lemic mice [73]. In many diseases, altering local synaptic connections
chronically, as happens in hyperglycemia, can change responses to
future synaptic input. For example, chronic GABA and glutamate
imbalance probably contributes to development of some forms of
epilepsy [91,92] and other brain disorders. Thus, altered glucose levels
can acutely change GABAergic and glutamatergic synaptic balance in
key brain areas. These changes in synaptic balance can, in turn, result
in longer-lasting changes in brain function that can outlast the initial
stimulus and contribute to alterations in glucose metabolism over a
time course that far exceeds the seconds to minutes required to alter
neuronal activity acutely.
Analogous to disorders like temporal lobe epilepsy, a “synaptic
imbalance” hypothesis proposes that modulation of otherwise normal
synaptic control of central autonomic circuits alter parasympathetic
function and consequently contributes to diabetes. A recent rando-
mized controlled trial on obese patients showed that participants who
underwent adjustable gastric banding surgery were most likely
achieve remission from type 2 diabetes and greater weight loss versus
control subjects, who participated in a conventional therapy program
that included mainly lifestyle modiﬁcations [93]. The observation
suggests that the degree of weight loss has a critical impact and could
be a major driving force of glycemic improvement and diabetes
remission in obese patients. It also implies that any contribution to
diabetes of altered synaptic regulation in autonomic circuits can be
reversed. Thus, controlling feeding and digestive behaviors—functions
that are regulated by autonomic circuits in the hypothalamus and
brainstem—seem likely to positively contribute to glycemic control. In
addition, some diabetic symptoms can begin to remediate prior to
signiﬁcant weight loss, suggesting additional mechanisms beyond
weight loss for normalizing glucose. Speculatively, gastric banding
and consequently the chronic alteration of gastric mechanoreceptor
activity would tend to diminish vagal visceroafferent signaling in the
NTS. Thismight be predicted to stabilize vagal function and act to reset
the level of tonic vagal efferent activity. The stabilization of
preganglionic vagal motor neuron activity might subsequently affect
both hepatic gluconeogenesis and insulin secretion. These effects
would be expected to occur rapidly and in addition to any modulation
of gastrointestinal function that contributes to altered ingestive
behavior. The contribution of central autonomic pathways to main-
tenance or control of diabetic symptoms is a promising avenue for
future research in controlling diabetes. An important requisite of such
therapeutic aims is the ability to modulate synaptic inputs
pharmacologically.
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Activity of numerous factors acting in brain circuits have been
identiﬁed as contributors to control of homeostatic functions. Here, we
will discuss contribution of one of the most malleable neurochemical
systems involved in the brain's control of metabolism, the cannabinoid
(CB) system. A large effort has been extended in the last few years to
understand the endocannabinoid system in the context of treating
obesity and relatedmetabolic disorders [94], but effects of cannabinoids
onneuronscontrollingenergymetabolismareonlypartiallyunderstood.
The behavioral effects on appetite of modulating the CB system are
well known [95]. The two best studied endogenously synthesized and
released cannabinoid agonists (eCB) are arachidonylethanolamine
(anandamide; AEA) and 2-arachidonylglycerol (2-AG). In general
terms, type 1 CB receptors (CB1R) are activated centrally after brief
food deprivation and these tend to upregulate orexigenic and
downregulate anorexigenic mediators of food consumption. Several
studies have provided evidence that the level of CB1R is high in
hypothalamic and brainstem areas involved in regulation of satiety,
food intake, and autonomic function [96,97]. The distribution of these
receptors suggests that they could directly regulate the expression of
orexigenic and anorexigenic signals and also modulate autonomic
circuits [98]. The CB receptors are also present in peripheral cells,
including hepatocytes [99], white adipose tissue [100], and pancreatic
β-cells [100,101]. These distributions suggest that peripheral eCB
activity is also involved in metabolic control, possibly by regulating
insulin levels, glucose uptake, and glucose production [101].
There is growing evidence suggesting that patients with hypergly-
cemia caused by type 2 diabetes have elevated levels of AEA and 2-AG
compared to non-diabetic controls [100,102]. Elevated plasma eCB
levels suggest that the eCBs are overproduced or their metabolism has
been decreased. This seems to accompany metabolic and eating
disorders and may contribute to the development of abdominal
obesity, dyslipidemia and hyperglycemia [95]. In the hypothalamus
and brainstem, eCBs have profound effects on synaptic inputs to
neurons involved in neuroendocrine and autonomic regulation.
Speciﬁcally, inhibitory synaptic inputs to both DMV motor neurons
[97] and to hypothalamic neuroendocrine neurons [103] are sup-
pressed by CB1R activation, consistent with increased feeding and
other known CB effects on energy homeostasis. Fig. 3 illustrates a
model for actions of cannabinoid activity at the synaptic level in
central autonomic circuits.
In addition, eCBs can exert neuro-protective effects in many CNS
related disorders, such as cerebral ischemia, stroke, neuronal injury
and neurodegenerative diseases, like multiple sclerosis, Huntington's
and Parkinson's disease [104]. The synthetic cannabinoid HU-210 may
have a protective effect in an experimental model of type 1 diabetes
[105]. In several brain areas CB1R activation modulates cellular
glucose utilization [106]. In animals with streptozotocin-induced
type 1 diabetes, the densities of CB1R protein and the speciﬁc CB1R
binding sites in the hippocampus were increased in nerve terminals
and in total membranes, whereas CB1R mRNA expression was
decreased [107]. These data suggest that CB1R play a role in diabetic
encephalopathy. Another study showed down-regulation of CB1R in
PC12 cells treated with high glucose and in sensory dorsal root
ganglion neurons from diabetic rats [108]. These data suggested that
the elevated plasma glucose that occurs in diabetes mellitus can be
associated with decreased expression of CB1R and altered eCB activity.
To complicate the issue, AEA has the ability to activate both CB1R
and transient receptor potential vanilloid type 1 and/or 4 (TRPV1,
TRPV4) receptors (Fig. 3). Activation of TRPV1 by AEA has an
excitatory effect and typically enhances synaptic transmission, but
this enhanced release of neurotransmitter can also be inhibited by
CB1R activation in some central neurons [109]. CB1R and TRPV1 are
co-localized in numerous brain areas, including areas which are
responsible for energy and glucose homeostasis [96,97,109]. In thedorsal root ganglia of animal models of type 1 diabetes, TRPV1
receptor protein is upregulated [110] and the neurons showed a
signiﬁcant increase in capsaicin-evoked inward currents. This obser-
vation coincides with other reported changes in type 1diabetic
animals [107,108], where the increasing glucose levels altered CB1R
expression levels. These ﬁndings are consistent with the emerging
hypothesis that CB1R/TRPV balance in autonomic areas could be
crucial regulators of glucose homeostasis and therefore in complicat-
ing and/or contributing to effects of diabetes. This altered function can
have a strong inﬂuence on autonomic output, including hepatic
gluconeogenesis but may also provide a possible therapeutic target to
better regulate glucose levels in patients with diabetes.
Finally, cannabinoid receptors may act as a substrate for other
potent modulators of metabolic function. For example, very recent
observations showed that ghrelin and the eCBs stimulate appetite via
activation of AMPK. Rimonabant, a CB1R antagonist, can block the
effects of ghrelin on feeding behavior, and ghrelin did not have effect
on CB1R knockoutmice [111]. Interestingly, leptin signaling in the PVN
also appears to involve the induction of eCB release and subsequent
binding to presynaptic CB1R on glutamate terminals contacting PVN
neurons [112]. Ghrelin also increases eCB levels in the hypothalamus
and inhibits EPSCs in parvocellular PVN neurons. Based on these
observations, an intact eCB signaling pathway appears to be required
for the effects of ghrelin on AMPK activity and food intake and for the
inhibitory effect of ghrelin and leptin on PVN neurons [111].
12. Conclusions
Precise regulation of autonomic function and hepatic gluconeo-
genesis is necessary to maintain appropriate energy sources. Recent
observations provide strong evidence in support of an important
pathway for brain–liver interactions, which connects lipid and peptide
sensing in the hypothalamus and brainstem to hepatic glucose
homeostasis [17,18,23]. In addition, vagal signaling and direct glucose
sensing in the vagal complex could mediate some of the brain's
responses to changes in plasma glucose concentration [40,43]. Current
data support the hypothesis that insulin acts at least partly through
central KATP channels to modulate central autonomic centers in the
hypothalamus and brainstem to inhibit hepatic glucose production.
Many effects of insulin, leptin, and glucose on hypothalamic or other
central autonomic circuits require intact vagal outﬂow through the
hepatic branch of the vagus. Neural activity is altered at the level of
central synapses in diabetes models, and this is reﬂected in
signiﬁcantly modiﬁed vagal motor function in animal models of
diabetes and in patients. Among the numerous modulators that may
be targeted to regulate metabolic output, the endogenous cannabi-
noids represent an emerging system for affecting control over
homeostatic functions. To improve health outcomes and quality of
life requires early and intensive treatment of diabetes [93]. Modula-
tion of central autonomic circuitry in the hypothalamus and/or
brainstem represents a potential therapeutic target for managing
glucose metabolism in diabetic patients.Acknowledgement
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